AU2001285042A1 - Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor - Google Patents
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitorInfo
- Publication number
- AU2001285042A1 AU2001285042A1 AU2001285042A AU8504201A AU2001285042A1 AU 2001285042 A1 AU2001285042 A1 AU 2001285042A1 AU 2001285042 A AU2001285042 A AU 2001285042A AU 8504201 A AU8504201 A AU 8504201A AU 2001285042 A1 AU2001285042 A1 AU 2001285042A1
- Authority
- AU
- Australia
- Prior art keywords
- peripheral
- methods
- cell lymphoma
- histone deacetylase
- deacetylase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 title 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 title 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 title 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 title 1
- 201000005962 mycosis fungoides Diseases 0.000 title 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22623400P | 2000-08-18 | 2000-08-18 | |
| US60/226,234 | 2000-08-18 | ||
| PCT/US2001/025827 WO2002015921A2 (en) | 2000-08-18 | 2001-08-17 | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001285042A1 true AU2001285042A1 (en) | 2002-03-04 |
Family
ID=22848093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001285042A Abandoned AU2001285042A1 (en) | 2000-08-18 | 2001-08-17 | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001285042A1 (en) |
| WO (1) | WO2002015921A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1443928B1 (en) | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| BR0308250A (en) | 2002-03-04 | 2005-01-11 | Aton Pharma Inc | Terminal Differentiation Induction Methods |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0226855D0 (en) | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
| US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7604939B2 (en) | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TWI415603B (en) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| WO2007011626A2 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2012801A4 (en) | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | Gemcitabine combination therapy |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| MX2008016503A (en) * | 2006-06-28 | 2009-06-08 | Novartis Ag | Use of hdac inhibitors for the treatment of lymphomas. |
| GB0620823D0 (en) | 2006-10-19 | 2006-11-29 | Univ London | Histone deacetylase inhibitors |
| US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
| AU2011279303B2 (en) | 2010-07-12 | 2015-07-16 | Celgene Corporation | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| PT2688572T (en) * | 2011-03-21 | 2017-06-02 | Valcuria Ab | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124495A (en) * | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
-
2001
- 2001-08-17 AU AU2001285042A patent/AU2001285042A1/en not_active Abandoned
- 2001-08-17 WO PCT/US2001/025827 patent/WO2002015921A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002015921A3 (en) | 2003-08-07 |
| WO2002015921A2 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001285042A1 (en) | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor | |
| AU2001298014A1 (en) | Inhibition of specific histone deacetylase isoforms | |
| AU2001282886A1 (en) | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain | |
| AU2001249918A1 (en) | Inhibitors of inflammation and reperfusion injury and methods of use thereof | |
| PL364175A1 (en) | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | |
| IL154574A0 (en) | Hydroxamate derivatives useful as deacetylase inhibitors | |
| AU2002309523A1 (en) | A brachytherapy device and method of use | |
| AU2001253126A1 (en) | (+) naloxone and epinephrine combination therapy | |
| AU2003209202A1 (en) | Method and device to treat vulnerable plaque | |
| AU2003286249A1 (en) | Histone deacetylase inhibitors | |
| HUP0400668A3 (en) | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof | |
| GB0005199D0 (en) | Modulation of histone deacetylase | |
| WO2001085201A3 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis | |
| AU2002315229A1 (en) | Histone deacetylase and methods of use thereof | |
| AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
| AU2002212350A1 (en) | Regulation of human histone deacetylase | |
| AU2001265182A1 (en) | Inhibitors of matrix metalloproteinases | |
| AU2003299815A1 (en) | Matriptase inhibitors and methods of use | |
| AU2002215018A1 (en) | Human histone deacetylase gene | |
| AU2001241498A1 (en) | Matrix metalloproteinase inhibitors and uses thereof | |
| AU6795000A (en) | Defense-related signaling genes and methods of use | |
| AU2002225915A1 (en) | Antisense modulation of histone deacetylase 1 expression | |
| AU2003294110A1 (en) | Use of a histone deacetylase inhibitor for treating muscular dystrophies | |
| AU2001292818A1 (en) | Use of transcription factors for treating inflammation and other diseases | |
| AUPQ582400A0 (en) | A method of treatment and agents for use therein |